Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation
Journal of the American Society of Nephrology · 2026-10 · 37 (10S)
DOI: 10.1681/asn.202644e83yca ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2026-10. Verfasst von Roberta Fenoglio und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Fenoglio, R., Sciascia, S., & Roccatello, D. (2026). Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation. Journal of the American Society of Nephrology, 37(10S). https://doi.org/10.1681/asn.202644e83yca
Vancouver
Fenoglio R, Sciascia S, Roccatello D. Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation. Journal of the American Society of Nephrology. 2026;37(10S). doi:10.1681/asn.202644e83yca
BibTeX
@article{Fenoglio2026,
author = {Fenoglio, Roberta and Sciascia, Savino and Roccatello, Dario},
title = {Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {10S},
doi = {10.1681/asn.202644e83yca}
}
EUVIMED